SEC Form 4 · accession 0001140361-19-001802
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas J Swirsky
Officer — President and CEO · Director
Period of report
Jan 29, 2019
Accepted (ET)
Jan 30, 2019 · 7:32 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 29, 2019 | P | 50,000 | $0.6344 | A | 50,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price of $0.6344 per share represents a weighted average of purchase prices ranging from $0.6097 to $0.6386 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.